Healthcare Industry News:  degenerative disc disease 

Devices Orthopaedic Neurosurgery

 News Release - September 17, 2012

Lanx Announces New Clinical Data That Show 94% Fusion Rate With ASPEN(TM) MIS Fusion System

Patient Outcomes Presented at Western Neurosurgical Society Meeting

BROOMFIELD, Colo., Sept. 17, 2012 -- (Healthcare Sales & Marketing Network) -- Lanx, Inc., a privately held medical device company focused on developing and commercializing innovative devices for spinal surgery, today announced new clinical data demonstrate a 94% fusion rate and positive clinical outcomes achieved with the ASPEN(TM) MIS Fusion System, providing further evidence that minimally invasive spinous process fixation offers effective stabilization to promote fusion and pain reduction. The data were presented at the Western Neurosurgical Society annual meeting held September 7-10 in Colorado Springs, CO.

Dan Gladney, Chief Executive Officer, Lanx, said, "These data help substantiate the clinical equivalency of the ASPEN system to traditional pedicle screws in promoting fusion, a finding that is widely supported by surgeon experience. The ASPEN device was developed to be a minimally invasive alternative to pedicle screws in the appropriate cases, allowing surgeons to best tailor fusion procedures to patients' needs, and we are encouraged by continued research supporting the positive outcomes achieved with the system."

The study, presented by Amir Vokshoor, MD, of the Institute of Neurosurgical Innovation, Marina del Rey, CA, evaluated 85 consecutive patients who underwent lumbar fusion with the ASPEN system. An independent radiologist used post-operative CT imaging to assess posterior fusion, as well as interbody fusion when applicable, and found it was successfully achieved in 94% of patients. Additionally, pain reduction was evaluated using Visual Analog Scale (VAS) values measured pre-operatively and post-operatively for up to 2 years, with findings demonstrating a clinically and statistically significant improvement from an average score of 6.5/10 pre-operatively to 2.9/10 within three months following surgery. This level of improvement was maintained throughout the follow-up period.

The ASPEN system is currently being used in a wide range of surgical applications including posterior lumbar fusions (PLF) and interbody fusions (PLIF, TLIF, ALIF and Lateral) for the treatment of degenerative disc disease, spondylolisthesis, spinal trauma or spinal tumor. For more information about the ASPEN MIS Fusion System or Lanx, please visit www.lanx.com.

About Lanx, Inc.

Lanx is one of the largest privately held global spine companies. The Company was founded by a team of experienced medical device professionals and engineers in 2003 to improve the quality of spine care and provide surgeons with innovative products. Lanx develops and markets a full line of fusion technologies with a focus on minimally invasive and biologics products. The Company is headquartered in Broomfield, CO. More information on Lanx and its spinal surgery products can be found at www.lanx.com.


Source: Lanx

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.